All In MedTech

FDA Clearance Tracker · P130009-S057

EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 18, 2016 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 18, 2016

Approved

Time to decision

108 days

Received May 2, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P130009-S057
Device name
EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE AND ACCESSORIES
Applicant location
Irvine, CA
Received
May 2, 2016
Decided
Aug 18, 2016
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Expedited review
Yes, flagged as expedited in FDA's record.
Original approval
P130009

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for the Edwards SAPIEN XT Transcatheter Heart Valve and accessories for expanding the indication to include patients with intermediate surgical risk for aortic valve replacement. The device is indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality >= 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.